Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia

被引:0
作者
Charles Bechert
Jee-Yeon Kim
Trine Tramm
Fattaneh A. Tavassoli
机构
[1] Yale University,Department of Pathology, School of Medicine
[2] Pusan National University,Department of Pathology, School of Medicine
[3] Aarhus University Hospital,Department of Pathology
来源
Virchows Archiv | 2016年 / 469卷
关键词
p16; p53; Ductal intraepithelial neoplasia (DIN); Ductal carcinoma in situ (DCIS); Immunohistochemistry;
D O I
暂无
中图分类号
学科分类号
摘要
In the USA alone, approximately 61,000 new diagnoses of ductal intraepithelial neoplasia 1c-3 (DIN) are made each year. Around 10–20 % of the patients develop a recurrence, about 50 % of which are invasive. Prior studies have shown that invasive breast carcinomas positive for p16 or p53 have a higher frequency of recurrence and a more aggressive course; however, the co-expression of these markers across the entire spectrum of DIN and its potential correlation with grade of the lesions has not been studied previously. Immunohistochemical staining for p16 and p53 was evaluated on 262 DIN lesions from 211 cases diagnosed between 1991 and 2008. The lesions ranged from DIN1b (atypical intraductal hyperplasia) to DIN3 (DCIS, grade 3) and included 45 cases with associated invasive carcinoma. Frequency of staining for both p16 and p53 increased with increasing grade of DIN. Strong co-expression was found exclusively in higher grade DIN lesions (DIN2 and DIN3) particularly those associated with periductal stromal fibrosis and lymphocytic infiltrate. Strong co-expression was seen in 8 of 12 DIN3 lesions (67 %) associated with invasive carcinoma. In conclusion, co-expression of p16 and p53 increases with advancing grade of DIN and is maximal in high grade DIN lesions associated with invasive carcinoma, indicating a more aggressive phenotype. A distinctive variant of DIN with periductal fibrosis and lymphocytic infiltrate invariably falls into the high-grade category, based on either morphology or marker expression. Co-expression of p16/p53 may be of help in distinguishing between high-grade and low-grade DIN lesions.
引用
收藏
页码:659 / 667
页数:8
相关论文
共 339 条
[1]  
Siegel RL(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30
[2]  
Miller KD(2000)The consensus conference on the treatment of in situ ductal carcinoma of the breast, 22-25 April 1999 Breast 9 177-186
[3]  
Jemal A(2007)Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast—results from the Swedish randomised trial Eur J Cancer 43 291-298
[4]  
Schwartz GF(2003)Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy J Natl Cancer Inst 95 1692-1702
[5]  
Solin LJ(2015)ACR appropriateness criteria(R) ductal carcinoma in situ Oncology (Williston Park) 29 446-458
[6]  
Olivotto IA(2001)Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ Br J Cancer 84 539-544
[7]  
Ernster VL(2005)Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Am J Surg 190 521-525
[8]  
Pressman P(2004)Ductal carcinoma in situ of the breast N Engl J Med 350 1430-1441
[9]  
Ringberg A(1998)Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast Mod Pathol 11 1151-1159
[10]  
Nordgren H(2007)Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors Cancer Cell 12 479-491